ArticlePloS one2020
Stakeholder perspectives on large-scale marine protected areas.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-scale marine protected areas (LSMPAs), MPAs greater than 100,000km2, have proliferated in the past decade. However, the value of LSMPAs as conservation tools is debated, in both global scientific and policy venues as well as in particular sites. To add nuance and more diverse voices to this debate, this research examines the perspectives of stakeholders directly engaged with LSMPAs. We conducted a Q Method study with forty LSMPA stakeholders at five sites, including three established LSMPAs (the Marianas Trench Marine National Monument, United States; the Phoenix Islands Protected Area, Kiribati; the National Marine Sanctuary, Palau) and two sites where LSMPAs had been proposed at the time of research (Bermuda and Rapa Nui (Easter Island), Chile). The analysis reveals five distinct viewpoints of LSMPAs. These include three more optimistic views of LSMPAs we have named Enthusiast, Purist, and Relativist. It also depicts two more cautious views of LSMPAs, which we have named Critic and Skeptic. The findings demonstrate the multi-dimensionality of stakeholder viewpoints on LSMPAs. These shared viewpoints have implications for the global LSMPA debate and LSMPA decision-makers, including highlighting the need to focus on LSMPA consultation processes. Better understanding of these viewpoints, including stakeholder beliefs, perspectives, values and concerns, may help to facilitate more nuanced dialogue amongst LSMPA stakeholders and, in turn, promote better governance of LSMPAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.